Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
In September 2022, the government ruled in Huadongs favor, but Novo appealed that decision
Abstract In the SELECT trial, once-weekly subcutaneous semaglutide reduced major adverse cardiovascular events (MACE) by 20% versus placebo in patients with atherosclerotic cardiovascular disease and obesity but without diabetes
These results suggest that GLP-1 may improve exercise endurance in mice by enhancing skeletal muscle glycogen synthesis and glucose uptake
Klarity Health connects psychiatrists and PMHNPs with pre-screened patients seeking both mental health and metabolic support with built-in telehealth infrastructure, insurance and cash-pay options, and a pay-per-appointment model that eliminates marketing risk
Sales of GLP-1 medicines for Type 2 diabetes grew 22% in 2024 to $24 billion, making them the largest category within Novo
US$ 23.29
US$ 23.39
US$ 25.11
US$ 21.80
US$ 26.10
US$ 20.57
US$ 24.74
US$ 20.04
US$ 25.37
US$ 24.17
US$ 22.88
US$ 21.08
US$ 24.57
US$ 29.71
US$ 29.15
US$ 22.75
